SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
暂无分享,去创建一个
G. Meno-Tetang | C Bruns | C. Bruns | I. Lewis | U. Briner | G. Weckbecker | I Lewis | U Briner | G Meno-Tetang | G Weckbecker | C. Bruns | Gisbert Weckbecker
[1] J. Rivier,et al. SST3-selective potent peptidic somatostatin receptor antagonists. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[2] B. Posner,et al. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. , 1992, Endocrinology.
[3] S. Melmed,et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. , 1997, The Journal of clinical investigation.
[4] D. Coy,et al. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. , 1987, Life sciences.
[5] W. Young,et al. Erratum: Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study (Journal of Clinical Endocrinoloy and Metabolism (1995) 80 (2768-2775)) , 1995 .
[6] A. Schally,et al. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. , 1987, Life sciences.
[7] M. Lebl,et al. Peptides: The Wave of the Future , 2001, American Peptide Symposia.
[8] E. Kohner,et al. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. , 1989, Acta endocrinologica.
[9] W. Meyerhof. The elucidation of somatostatin receptor functions: a current view. , 1998, Reviews of physiology, biochemistry and pharmacology.
[10] B H Arison,et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[11] W. Young,et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.
[12] F. Raulf,et al. Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201‐995 for the SSTR2 somatostatin receptor. , 1995, The EMBO journal.
[13] E. Krenning,et al. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.
[14] S. Lamberts,et al. Drug therapy : octreotide , 1996 .
[15] D. Hoyer,et al. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[16] A. Hoffman,et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. , 2001, Endocrinology.
[17] Y. Patel. Molecular pharmacology of somatostatin receptor subtypes , 1997, Journal of endocrinological investigation.
[18] Y. Patel. Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.
[19] U. Kumar,et al. Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers* , 2000, The Journal of Biological Chemistry.
[20] D. Hoyer,et al. Molecular pharmacology of somatostatin receptors , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.
[21] T. Stijnen,et al. Effect of Long-Acting Somatostatin Analog (Somatulin) on Renal Hyperfiltration in Patients With IDDM , 1997, Diabetes Care.
[22] S. Melmed,et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. , 1997, The Journal of clinical investigation.
[23] U. Kumar,et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.
[24] P. Marbach,et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.
[25] T. Kissel,et al. Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. , 1991, Gastroenterology.
[26] W. Millard,et al. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization , 1993, Regulatory Peptides.
[27] G. Liapakis,et al. Development of a selective agonist at the somatostatin receptor subtype sstr1. , 1996, The Journal of pharmacology and experimental therapeutics.
[28] H. Orskov,et al. Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention. , 1995, The Journal of endocrinology.
[29] J. Epelbaum. Somatostatin in the central nervous system: Physiology and pathological modifications , 1986, Progress in Neurobiology.
[30] J. Luo,et al. Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide, CYN-154806 , 2000, Neuropharmacology.
[31] A. Schonbrunn. Somatostatin receptors present knowledge and future directions. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] M. Dashkevicz,et al. Nonpeptidyl somatostatin agonists demonstrate that sst2 and sst5 inhibit stimulated growth hormone secretion from rat anterior pituitary cells. , 1999, Biochemical and biophysical research communications.
[33] P. Caron,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society BIM-23244, a Somatostatin Receptor Subtype 2- and 5- Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide- , 2022 .
[34] Jun. Octreotide , 1989, The Lancet.
[35] N. Ling,et al. Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.
[36] Molecular biology of somatostatin receptors. , 1995, Endocrine reviews.
[37] D. Hoyer,et al. Binding properties of somatostatin receptor subtypes. , 1996, Metabolism: clinical and experimental.
[38] A. Harris,et al. Octreotide and diabetes: theoretical and experimental aspects. , 1992, Metabolism: clinical and experimental.
[39] R G Smith,et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.